Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Vaccine Strategies for HPV-Related Cancers
share announcement

Vaccine Strategies for HPV-Related Cancers

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 31 July 2024 | Viewed by 4382

Special Issue Editor

Prof. Dr. Diane M. Harper

E-Mail Website
Guest Editor
1. Departments of Family Medicine and Obstetrics & Gynecology, University of Michigan, Ann Arbor, MI, USA
2. Department of Biomedical Engineering, U-M College of Engineering, University of Michigan, Ann Arbor, MI, USA
3. Department of Women's and Gender Studies, U-M College of Literature, Science, and the Arts, University of Michigan, Ann Arbor, MI, USA
Interests: HPV associated diseases; screening and prevention of cervical cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Human papillomavirus (HPV) vaccines were purposefully designed to cover HPV 16 and 18, which are associated with about 70% of cervical cancers and about 90% of HPV-associated head & neck and anal cancers. Enough time has elapsed to see early indicators of the reduction in cancers associated with HPV. Other types of HPV will be clinically unmasked as the natural infection types are blocked. Following the change in distribution of HPV types causing the associated cancers will be important to note so that the modeling studies for future prognostic health planning can be modified. HPV vaccine administration appears to be sufficient at one dose for children 9 years of age. Increasing population coverage with a single dose offers more efficiency and equity in vaccine distribution. Understanding person-level and population-level barriers and facilitators to the original vaccine uptake are needed. Separately, the development of pan-HPV vaccines as the next generation vaccine is imperative. Continuing to leave oncogenic HPV types out of the vaccine perpetuates HPV-associated cancer inequities.

Dr. Diane M. Harper
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HPV vaccine uptake
  • single dose immunization
  • clinical unmasking
  • HPV-associated cancers

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 269 KiB  
Article
Selecting and Tailoring Implementation Strategies to Improve Human Papillomavirus Vaccine Uptake in Zambia: A Nominal Group Technique Approach
by Mwansa Ketty Lubeya, Mulindi Mwanahamuntu, Carla J. Chibwesha, Moses Mukosha and Mary Kawonga
Vaccines 2024, 12(5), 542; https://doi.org/10.3390/vaccines12050542 - 15 May 2024
Viewed by 231
Abstract
The human papillomavirus (HPV) vaccine is effective in cervical cancer prevention. However, many barriers to uptake exist and strategies to overcome them are needed. Therefore, this study aimed to select and tailor implementation strategies to barriers identified by multiple stakeholders in Zambia. The [...] Read more.
The human papillomavirus (HPV) vaccine is effective in cervical cancer prevention. However, many barriers to uptake exist and strategies to overcome them are needed. Therefore, this study aimed to select and tailor implementation strategies to barriers identified by multiple stakeholders in Zambia. The study was conducted in Lusaka district between January and February 2023. Participants were purposively sampled from three stakeholder groups namely, adolescent girls, parents, and teachers and healthcare workers. With each of the stakeholders’ groups (10–13 participants per group), we used the nominal group technique to gain consensus to tailor feasible and acceptable implementation strategies for mitigating the identified contextual barriers. The identified barriers included low levels of knowledge and awareness about the HPV vaccine, being out of school, poor community sensitisation, lack of parental consent to vaccinate daughters, and myths and misinformation about the HPV vaccine. The lack of knowledge and awareness of the HPV vaccine was a common barrier across the three groups. Tailored strategies included conducting educational meetings and consensus-building meetings, using mass media, changing service sites, re-examining implementation, and involving patients/consumers and their relatives. Our study contributes to the available evidence on the process of selecting and tailoring implementation strategies to overcome contextual barriers. Policymakers should consider these tailored strategies to mitigate barriers and improve HPV vaccine uptake. Full article
(This article belongs to the Special Issue Vaccine Strategies for HPV-Related Cancers)
14 pages, 1448 KiB  
Article
Human Papilloma Virus Vaccination and Cervical Screening in the Italian Regions: An Overview of the Current State of the Art
by Angela Bechini, Claudia Cosma, Giulia Di Pisa, Alice Fanfani, Giulia Ionita, Davide Liedl, Carla Lunetta, Linda Martorella, Silvia Mele, Lorenzo Stacchini, Gabriele Vaccaro, Ornella Zuccaro, Stefano Valente, Gian Marco Prandi, Paolo Bonanni and Sara Boccalini
Vaccines 2024, 12(5), 504; https://doi.org/10.3390/vaccines12050504 - 7 May 2024
Viewed by 368
Abstract
Human Papilloma Virus (HPV) infection and HPV-related cancers can be prevented through vaccinations and mass cervical screening programmes. The Ministry of Health in Italy provides recommendations on primary and secondary prevention of HPV-related diseases, but the 19 Italian regions and 2 autonomous provinces [...] Read more.
Human Papilloma Virus (HPV) infection and HPV-related cancers can be prevented through vaccinations and mass cervical screening programmes. The Ministry of Health in Italy provides recommendations on primary and secondary prevention of HPV-related diseases, but the 19 Italian regions and 2 autonomous provinces have organisational and decision-making autonomy, with differences in the strategies for offering prevention. The aim of this study is to describe the HPV vaccination and cervical screening offered in all Italian regions. Regional official documents up until 31 December 2021 were first identified. Subsequently, primary and secondary prevention experts from each region were interviewed to validate the previously collected data. The National Immunisation Plan (NIP) 2017–2019 recommends HPV vaccination from the age of 11 for both sexes, with a coverage target of 95%. HPV vaccination is offered free of charge or co-payment. All regions have screening programmes for cervical cancer, using PAP or HPV-DNA tests every three to five years. All regions have an electronic registry for vaccination and screening status. All regions have developed awareness-raising campaigns. It is important to harmonise regional policies with the implementation of information systems integration. The collected data could enhance both regional and national public health initiatives, bolstering the resilience of vaccination programs. Full article
(This article belongs to the Special Issue Vaccine Strategies for HPV-Related Cancers)
►▼ Show Figures

Figure 1

16 pages, 788 KiB  
Article
Understanding Barriers to Human Papillomavirus Vaccination among Parents of 9–10-Year-Old Adolescents: A Qualitative Analysis
by Denny Fe G. Agana-Norman, Monica Martinez Martinez, Manjushree Shanmugasundaram and Abbey B. Berenson
Vaccines 2024, 12(3), 245; https://doi.org/10.3390/vaccines12030245 - 27 Feb 2024
Viewed by 1632
Abstract
HPV vaccination rates remain low among US adolescents, with only 54% completing the series in 2019. The vaccine is recommended at age 11–12 but can be given as early as age 9. Although it has been found that offering the vaccine earlier improves [...] Read more.
HPV vaccination rates remain low among US adolescents, with only 54% completing the series in 2019. The vaccine is recommended at age 11–12 but can be given as early as age 9. Although it has been found that offering the vaccine earlier improves completion rates by age 13, parents remain reluctant to allow their younger children to initiate this vaccine. The purpose of this study was to better understand parental beliefs regarding receipt of the HPV vaccine among their children at ages 9–10. A 40 min phone interview was completed with 21 participants who were asked about their vaccine viewpoints. Even after receiving one-on-one education from a patient navigator, many caretakers expressed inadequate knowledge of the HPV vaccine and limited exposure to both positive and negative influences. The biggest concern was vaccine side effects, often resulting from a lack of medical understanding. Most parents were reluctant to vaccinate their children at a school-based clinic or pharmacy and believed that the government should not mandate HPV vaccination for public school attendance. Our study provides insight into parental beliefs and attitudes about HPV vaccination at age 9–10 years and barriers that need to be addressed. Full article
(This article belongs to the Special Issue Vaccine Strategies for HPV-Related Cancers)

Review

Jump to: Research

13 pages, 641 KiB  
Review
Graduate and Health Professional Student Knowledge, Attitudes, Beliefs, and Behavior Related to Human Papillomavirus and Human Papillomavirus Vaccination: A Scoping Review of the Literature
by Joshua Gautreaux, Eric Pittman, Kennedy LaPorte, Jiaxin Yang and Marie Barnard
Vaccines 2024, 12(5), 507; https://doi.org/10.3390/vaccines12050507 - 7 May 2024
Viewed by 460
Abstract
Human papillomavirus (HPV) is a common sexually transmitted infection. Despite a safe and effective vaccine, uptake continues to be suboptimal. Recently, focus has moved to college campuses in an effort to increase vaccination rates. Little is known about the extent of efforts to [...] Read more.
Human papillomavirus (HPV) is a common sexually transmitted infection. Despite a safe and effective vaccine, uptake continues to be suboptimal. Recently, focus has moved to college campuses in an effort to increase vaccination rates. Little is known about the extent of efforts to reach graduate students on college campuses in the United States and the vaccination rates within this subpopulation. This scoping review assessed the literature on knowledge, attitudes, beliefs, and behaviors about HPV and HPV vaccination among graduate and post-baccalaureate professional students in the United States. This review also aims to identify areas for further research to improve institutions’ abilities to create health programming to increase HPV awareness and HPV vaccination coverage on their campuses. Publications focusing on knowledge, attitudes, beliefs, and behaviors about HPV and HPV vaccination in post-baccalaureate students were included. The systematic review of PubMed, CINAHL, and Embase identified 2562 articles, and 56 articles met all inclusion criteria and were included in this scoping review. A majority of the reviewed studies investigated some combination of knowledge, attitudes, behaviors, and beliefs about HPV and the HPV vaccine in students in professional programs such as medicine. Study design approaches were primarily cross-sectional, utilizing web-based survey distribution methods. HPV vaccination status and HPV screening behaviors were primarily measured through participant self-report. There is limited research investigating post-baccalaureate student knowledge, attitudes, beliefs, and behaviors about HPV and HPV vaccination. There is a need for researchers to further investigate the needs of graduate students to create informative and effective HPV programming. Full article
(This article belongs to the Special Issue Vaccine Strategies for HPV-Related Cancers)
►▼ Show Figures

Figure 1

15 pages, 317 KiB  
Review
Human Papillomavirus Vaccination in Pediatric, Adolescent, and Young Adult Cancer Survivors—Opportunity to Address Gaps in Cancer Prevention and Survivorship
by Melissa A. Kluczynski, Elisa M. Rodriguez, Cailey S. McGillicuddy and Nicolas F. Schlecht
Vaccines 2024, 12(2), 114; https://doi.org/10.3390/vaccines12020114 - 24 Jan 2024
Viewed by 1151
Abstract
The risks of secondary cancers associated with human papillomavirus (HPV) infection are as much as three times higher for survivors of pediatric, adolescent, and young adult cancer (PYAC) compared to the general population. Despite this, HPV vaccination rates among PYAC survivors remain low. [...] Read more.
The risks of secondary cancers associated with human papillomavirus (HPV) infection are as much as three times higher for survivors of pediatric, adolescent, and young adult cancer (PYAC) compared to the general population. Despite this, HPV vaccination rates among PYAC survivors remain low. Whereas pediatric oncology providers endorse HPV vaccination of PYAC survivors, many lack the resources or opportunities to intervene. The responsibility of HPV vaccination, therefore, falls to primary care providers and practices. This article provides an overview of the challenges with HPV vaccination that are distinct to PYAC survivors and discusses potential strategies to increase HPV vaccine coverage in this population. Full article
(This article belongs to the Special Issue Vaccine Strategies for HPV-Related Cancers)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: HPV Vaccination in Pediatric and Young Adult Cancer Survivors – Opportunity to Address Gaps in Cancer Prevention and Survivorship
Author: Schlecht
Highlights: • Despite increased risk for HPV-related secondary cancers among pediatric-and-young-adult cancer (PYAC) survivors, HPV vaccination rates remain low in this population. • Whereas pediatric oncology providers endorse HPV vaccination of PYAC survivors, the responsibility typically remains with primary care providers. • Cancer transition of care models that integrate evidence-based strategies offer an opportunity for increasing HPV vaccination rates among PYAC survivors.

Back to TopTop